Cannabis sativa is a remarkable plant, with an enormous level of variety of cannabinoids, flavonoids, terpenes and other products made possible through management of breeding. With heightened medical interest in the human endocannabinoid system, and the multitude of possibilities for a cannabis derived medicine to be developed, breeding and agriculture are likely to be central to new medicine development in a way we have never seen before.

Agri Fibre Industries (AFI), the parent company of Canndeo, commenced its Cannabis sativa breeding program in 1998, with the development of a range of Cannabis sativa plants for food, fibre and other uses from more than 100 parent lines. Its specialty was the quick development of functional plants to improve value of the plants while simultaneously reducing levels of THC.

Plant Breeders Rights

Plant Breeders Rights (PBR) confers exclusivity in plant use for commercial purposes to the registered owner, and is used in combination with other protection mechanisms (including contractual agreements on distribution and propagation) to enable commercial viability for developers of new breeds.

Australia has 12 varieties of Cannabis sativa registered under its PBR program by IP Australia. Of these, AFI has 6 granted and 1 accepted PBR. This dominance of PBR for Cannabis sativa in Australia is testament both to the quality of AFI’s breeding team and its long-term investment in new and valuable varieties.

Development Program

Inheriting this tradition and having access to all AFI’s breeds and breeding experts, Canndeo will continue to work closely with AFI on the medicinal use of current varieties as well as the development of new generation Cannabis sativa strains for medicinal use. Adding this capability to our broader collaboration in search of new and valuable medicines, Canndeo has positioned itself to become a leader in this emergent and high growth field.